Vir Stock Soars 12% After Hepatitis Delta Trial Meets Its Main Goal

The gain added $259 million in market value, extending a run that had already put shares up 103% this year through Friday.

Share
Vir Stock Soars 12% After Hepatitis Delta Trial Meets Its Main Goal

Vir Biotechnology, which develops experimental medicines for infectious diseases and cancer, soared 12.37% to $13.72 in Monday trading, as of 9:47 AM ET, adding $259 million in market value. The advance followed Sunday's announcement that its experimental hepatitis delta treatment met the main goal of a late-stage trial.

Undetectable Virus In 79%

Vir reported undetectable virus levels in 79% of treated patients after 48 weeks. The comparison group, whose treatment was delayed, registered 0% when assessed before treatment at 12 weeks—a different assessment period.

The study enrolled 124 patients and recorded one severe treatment-related adverse event. No patients interrupted or discontinued treatment.

The combination pairs elebsiran with tobevibart in a monthly injection. Vir's Wednesday earnings release described the trial as testing the combination against deferred treatment in the U.S. and other regions where bulevirtide use is limited.

A Rally Already Up 103%

Vir reached a new 52-week high in Monday trading, as of 9:47 AM ET, and was on pace for its second gain of 10% or more this month. Its total market value stood at about $2.35 billion in Monday trading, as of 9:47 AM ET.

Before Monday's advance, shares had gained 103% this year through Friday's close, compared with 8% for the S&P 500. That run came before confirmation of the hepatitis delta results management had been awaiting.

“We are entering an important period for Vir Bio, with meaningful catalysts across both hepatitis delta and oncology,” Marianne De Backer, president and chief executive officer of Vir Biotechnology, said in Wednesday's earnings release.

More Trials Before An Approval Bid

Vir expects results from two additional pivotal hepatitis delta trials in the first quarter of 2027. It plans to seek U.S. approval in mid-2027; data from all three trials are intended for a global application package.

Vir's medicines remain development candidates rather than products approved for sale. Beyond infectious diseases, it develops cancer treatments, uses its dAIsY artificial-intelligence engine to engineer antibodies, and licenses candidates both into and out of its pipeline.

The company also expects pivotal trials of its prostate cancer candidate VIR-5500 to begin in 2027 with Astellas. The program received FDA Fast Track designation, and Vir said it achieved proof of concept.

Vir reported negative revenue of $188,000 and a $96.3 million net loss for the third quarter. It ended the quarter with approximately $901 million in cash, cash equivalents and investments, excluding $90 million in upfront consideration from its Gilead collaboration to develop three cancer-treatment candidates.

The next hepatitis delta readouts are expected in the first quarter of 2027, ahead of Vir's planned mid-2027 U.S. approval application.

Sources

More on Vir Biotechnology

All Vir Biotechnology (VIR) coverage →